[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA115523C2 - Тверді форми макроциклічних інгібіторів кінази - Google Patents

Тверді форми макроциклічних інгібіторів кінази

Info

Publication number
UA115523C2
UA115523C2 UAA201306799A UAA201306799A UA115523C2 UA 115523 C2 UA115523 C2 UA 115523C2 UA A201306799 A UAA201306799 A UA A201306799A UA A201306799 A UAA201306799 A UA A201306799A UA 115523 C2 UA115523 C2 UA 115523C2
Authority
UA
Ukraine
Prior art keywords
kinase inhibitors
solid state
state forms
macrocyclic
macrocyclic kinase
Prior art date
Application number
UAA201306799A
Other languages
English (en)
Inventor
Роберт К. Менсфілд
Трейсі Левон
Браян Даймок
Original Assignee
Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка" filed Critical Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка"
Publication of UA115523C2 publication Critical patent/UA115523C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

В даному документі запропоновано сольові форми макроциклічних інгібіторів протеїнкінази – кристалічний цитрат структури 1 та кристалічний фумарат структури 2 14-метил-20-окса-5,7,14,27-тетраазатетрацикло-[19.3.1.12,6.18,12]гептакоза-1(25),2,4,6,8,10,12(26),16,21,23-декаєну, фармацевтичні композиції, що їх містять, способи виготовлення та використання цих сполук і композицій для лікування проліферативного захворювання, опосередкованого активністю кінази.
UAA201306799A 2010-02-05 2011-02-04 Тверді форми макроциклічних інгібіторів кінази UA115523C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30177110P 2010-02-05 2010-02-05
PCT/US2011/023810 WO2011097525A1 (en) 2010-02-05 2011-02-04 Solid state forms of macrocyclic kinase inhibitors

Publications (1)

Publication Number Publication Date
UA115523C2 true UA115523C2 (uk) 2017-11-27

Family

ID=44355815

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201306799A UA115523C2 (uk) 2010-02-05 2011-02-04 Тверді форми макроциклічних інгібіторів кінази

Country Status (6)

Country Link
US (1) US9120815B2 (uk)
EP (1) EP2531197B1 (uk)
EA (1) EA027622B1 (uk)
ES (1) ES2632548T3 (uk)
UA (1) UA115523C2 (uk)
WO (1) WO2011097525A1 (uk)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法
CA3018875A1 (en) * 2016-03-24 2017-09-28 Tragara Pharmaceuticals, Inc. Treatment of cancer with tg02
SG11202001441WA (en) 2017-08-18 2020-03-30 Tragara Pharmaceuticals Inc Polymorphic form of tg02
CN108864145B (zh) * 2018-09-14 2021-03-30 兆科（广州）肿瘤药物有限公司 一种氧联嘧啶衍生物的纯化方法
WO2020219603A1 (en) * 2019-04-22 2020-10-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of tg02 for treating gliomas in pediatric subjects

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
ATE268591T1 (de) 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
CA2275422A1 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
EP1951729B1 (en) * 2005-11-16 2014-06-25 Cell Therapeutics, Inc. Oxygen linked pyrimidine derivatives

Also Published As

Publication number Publication date
EA201390636A1 (ru) 2014-08-29
WO2011097525A1 (en) 2011-08-11
EA027622B1 (ru) 2017-08-31
ES2632548T3 (es) 2017-09-14
US20130150378A1 (en) 2013-06-13
US9120815B2 (en) 2015-09-01
EP2531197B1 (en) 2017-05-17
EP2531197A4 (en) 2013-12-11
EP2531197A1 (en) 2012-12-12

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
AU2018260809A1 (en) Compounds and uses thereof for the modulation of hemoglobin
AU2018260808A1 (en) Compounds and uses thereof for the modulation of hemoglobin
WO2014011900A3 (en) Inhibitors of the fibroblast growth factor receptor
MX2009010984A (es) Moduladores de heterociclo cinasa de anillo fusionado.
IL222918B (en) Derivatives of 4-amino-6-phenyl-pyridazine-3-one and 3-amino-5-phenyl-(pyridin/pyrazin)-2-one, pharmaceutical compositions comprising them and kit for treating a condition mediated by bruton’s tyrosine kinase comprising them
WO2013012915A9 (en) Heterocyclic compounds and uses thereof
MX2015007921A (es) Compuestos heterociclicos novedosos como inhibidores de bromodominio.
UA115767C2 (uk) Способи отримання ізохінолінонів і тверді форми ізохінолінонів
WO2014080291A3 (en) Biaryl derivatives as bromodomain inhibitors
EA201270722A1 (ru) Формы рифаксимина и их применение
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
WO2012050918A3 (en) Tricyclic fused ring inhibitors of hepatitis c
WO2014019908A3 (en) Substituted pyrroles active as kinases inhibitors
MY162950A (en) Compounds and methods for kinase modulation, and indications therefor
WO2012155066A3 (en) Spiro-oxindole mdm2 antagonists
AU2011328009A8 (en) Compounds and methods for treating pain
WO2012040389A3 (en) Substituted bicyclic hcv inhibitors
EA201370018A1 (ru) Составы рифаксимина и их применение
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
WO2012125981A3 (en) Raf kinase inhibitors
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
UA115523C2 (uk) Тверді форми макроциклічних інгібіторів кінази